Hoffmann, R. F.
Jonker, M. R.
Brandenburg, S. M.
de Bruin, H. G.
ten Hacken, N. H. T.
van Oosterhout, A. J. M.
Heijink, I. H.
Article History
Received: 9 October 2018
Accepted: 25 September 2019
First Online: 21 October 2019
Competing interests
: This study was funded by and performed within the framework of the Top Institute Pharma project T1-201 “COPD, transition of systemic inflammation into multi-organ pathology”, with partners of the University of Groningen, University Medical Center Groningen, University Medical Center Utrecht, University Medical Center Maastricht, Nycomed BV, GlaxoSmithKline, Danone, AstraZeneca and Foundation TI Pharma. We have no non-financial competing interests.